Vyome Holdings, Inc. (NASDAQ:HIND) Given Consensus Recommendation of “Hold” by Brokerages

Vyome Holdings, Inc. (NASDAQ:HIND) has earned a consensus rating of “Hold” from the five analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $15.00.

Several research firms have weighed in on HIND. Weiss Ratings upgraded shares of Vyome from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Litchfield Hills Research began coverage on shares of Vyome in a report on Monday, May 4th. They set a “buy” rating on the stock. Finally, Zacks Research upgraded shares of Vyome to a “hold” rating in a report on Wednesday, May 6th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Vyome stock. Geode Capital Management LLC acquired a new position in shares of Vyome Holdings, Inc. (NASDAQ:HIND) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned about 0.21% of Vyome at the end of the most recent quarter. Institutional investors and hedge funds own 22.06% of the company’s stock.

Vyome Trading Down 0.9%

HIND opened at $2.32 on Tuesday. Vyome has a 1-year low of $1.75 and a 1-year high of $33.16. The company has a market cap of $16.29 million, a P/E ratio of -0.19 and a beta of 1.48. The company has a fifty day moving average price of $2.17 and a two-hundred day moving average price of $3.02.

Vyome (NASDAQ:HIND) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter. Vyome had a negative net margin of 270.58% and a negative return on equity of 203.92%. The company had revenue of $0.03 million during the quarter. On average, research analysts forecast that Vyome will post -0.6 EPS for the current fiscal year.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.